Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Nonlinear Pharmacokinetics: Overview

Nonlinear Pharmacokinetics: Overview

Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Circulating levels of leptin in different phases of the menstrual cycle - A systematic review and meta-analysis.

Journal of family medicine and primary care·2026

Same author

Socioeconomic Outcomes of Childhood Cancer Survivors in India: A Cross-Sectional Study From a Tertiary Care Childhood Cancer Survivorship Program.

JCO global oncology·2026

Same author

Continuous Positive Airway Pressure Versus Mandibular Advancement Devices Impact on Cardio-Metabolic Outcomes in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Journal of sleep research·2026

Same author

Prostate cancer and diabetes: A retrospective analysis of mortality trends in the United States (1999-2024).

Medicine·2026

Same author

Anticoagulation alone vs anticoagulation plus antiplatelet therapy in atrial fibrillation with stable coronary disease: A meta-analysis of randomized trials.

Heart rhythm O2·2026

Same author

Genotype-Phenotype Discordance in Cardiomyopathies: Pathophysiology, Clinical Expression, and Therapeutic Considerations.

Health science reports·2026

Search research articles

Related Experiment Video

Updated: Jun 9, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

PCSK9 Inhibitors: The Evolving Future.

Bijay Mukesh Jeswani¹, Shubhangi Sharma², Sawai Singh Rathore³

¹Department of Medicine GCS Medical College, Hospital & Research Centre Ahmedabad India.

Health Science Reports

|October 31, 2024

Summary

PCSK9 inhibitors significantly reduce LDL cholesterol, lowering cardiovascular event risk in high-risk patients. These novel therapies offer an effective alternative for individuals unable to tolerate statins or with familial hypercholesterolemia.

Keywords:

PCSK9 inhibitors LDL cholesterol cardiovascular disease familial hypercholesterolemia proprotein convertase subtilisin/kexin type 9

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Experiment Videos

Last Updated: Jun 9, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Area of Science:

Cardiovascular Medicine
Pharmacology
Lipid Metabolism

Background:

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a novel therapeutic class for managing hypercholesterolemia.
These agents enhance LDL receptor activity, thereby increasing the clearance of low-density lipoprotein cholesterol (LDL-C) from circulation.
PCSK9 inhibitors are utilized as adjuncts to statin therapy or as monotherapy in patients at high cardiovascular risk.

Purpose of the Study:

To present an updated review of PCSK9 inhibitors, focusing on their clinical effectiveness, safety profile, and overall significance.
To assess the impact of recent clinical trials on the understanding and application of PCSK9 inhibition.

Main Methods:

Review of major cardiovascular outcome trials, including FOURIER, SPIRE-1, SPIRE-2, and ODYSSEY Outcomes.
Examination of the role of PCSK9 in cholesterol homeostasis.
Evaluation of emerging therapeutic strategies, such as small interfering RNA (siRNA) therapies, and their effects on LDL-C and lipoprotein(a) levels.

Main Results:

PCSK9 inhibitors demonstrated up to a 60% reduction in LDL-C levels across clinical trials.
Evolocumab (FOURIER) and alirocumab (ODYSSEY Outcomes) significantly reduced LDL-C and major adverse cardiovascular events.
Emerging therapies like Inclisiran offer sustained LDL-C reduction with infrequent dosing, and PCSK9 inhibitors are generally well-tolerated, with injection site reactions being the most common side effect.

Conclusions:

PCSK9 inhibitors are highly effective in lowering LDL-C and reducing cardiovascular risk, providing a vital treatment option for high-risk individuals, including those with familial hypercholesterolemia or statin intolerance.
Future research directions include optimizing PCSK9 inhibitor therapies, exploring combination treatments, and investigating gene-editing technologies for enhanced patient outcomes.